Exelixis, Inc. (NASDAQ:EXEL) Director Vincent T. Marchesi sold 15,000 shares of the stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $24.73, for a total value of $370,950.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Exelixis, Inc. (NASDAQ:EXEL) opened at $24.53 on Friday. The stock has a market capitalization of $7,270.00, a PE ratio of 50.06, a P/E/G ratio of 1.29 and a beta of 1.96. Exelixis, Inc. has a 1-year low of $18.03 and a 1-year high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.12. The business had revenue of $120.10 million for the quarter, compared to analysts’ expectations of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.12 earnings per share. equities analysts expect that Exelixis, Inc. will post 0.59 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of EXEL. Dimensional Fund Advisors LP boosted its holdings in Exelixis by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 620,096 shares of the biotechnology company’s stock valued at $15,273,000 after acquiring an additional 28,195 shares during the last quarter. Aperio Group LLC boosted its holdings in Exelixis by 8.9% in the third quarter. Aperio Group LLC now owns 63,557 shares of the biotechnology company’s stock valued at $1,540,000 after acquiring an additional 5,212 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in Exelixis in the third quarter valued at about $236,000. Crossmark Global Holdings Inc. bought a new position in Exelixis in the third quarter valued at about $239,000. Finally, Canada Pension Plan Investment Board boosted its holdings in Exelixis by 705.0% in the third quarter. Canada Pension Plan Investment Board now owns 371,900 shares of the biotechnology company’s stock valued at $9,011,000 after acquiring an additional 325,700 shares during the last quarter. Institutional investors and hedge funds own 79.62% of the company’s stock.
WARNING: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/2018/03/10/exelixis-inc-exel-director-sells-370950-00-in-stock/1998525.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.